With low levels of vitamin D in critically ill patients with COVID-19 reported in numerous recent studies, and evidence supporting the reasonably good absorption of enterally administered vitamin D, researchers conducted a study to determine the outcomes of boosting low levels in the vitamin D to Improve Outcomes by Leveraging Early Treatment (VIOLET) trial. For the study, 2,624 critically ill, vitamin D-deficient patients at high risk for death were administered a 540,000 IU boost of vitamin D3 or matched placebo within 12 hours of the decision for ICU admission. At 90 days, mortality rates were 23.5% in the vitamin D group and 20.6% in the placebo group. “There were no clinically important differences between the groups with respect to secondary clinical, physiological, or safety endpoints,” write the study authors. “The severity of vitamin D deficiency at baseline did not affect the association between the treatment assignment and mortality.” It has been suggested that vitamin D did not improve outcomes because a maintenance dose was not administered after the initial boost. The ongoing VITDALIZE trial is currently assessing this.
October 5, 2020
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.